Aprea Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 7.76 million compared to USD 15.39 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.73 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.299 USD | +5.50% | +0.34% | +12.74% |
05-14 | Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-02 | Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.74% | 28.77M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.55% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- APRE Stock
- News Aprea Therapeutics, Inc.
- Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021